Stay updated on Tepotinib & Gefitinib in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Tepotinib & Gefitinib in NSCLC Clinical Trial page.

Latest updates to the Tepotinib & Gefitinib in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedAn administrative revision tag 'Revision: v3.3.3' was added and the 'HHS Vulnerability Disclosure' link along with the previous 'Revision: v3.3.2' were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedPublications section updated to clarify that publications are provided voluntarily by the person entering study information. The revision tag is updated to v3.3.2, replacing the old v3.2.0 wording.SummaryDifference0.1%

- Check39 days agoChange DetectedThe page no longer shows the site-wide government funding status notice. The study details and data presented on the page remain unchanged.SummaryDifference0.2%

- Check60 days agoChange DetectedThe page content appears unchanged with no additions or deletions impacting core information, pricing, or availability.SummaryDifference0.2%

- Check83 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links; replaces v3.1.0.SummaryDifference1%

- Check90 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0, indicating a newer release.SummaryDifference0.0%

Stay in the know with updates to Tepotinib & Gefitinib in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tepotinib & Gefitinib in NSCLC Clinical Trial page.